Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia
Product Description:
Hypophosphatasia results from mutations in the gene for the tissue-nonspecific isozyme of alkaline phophatase (TNSALP). Inorganic pyrophosphate accumulates extracellularly, leading to rickets or osteomalacia. Severely affected babies often die from respiratory insufficiency due to progressive chest deformity or have persistent bone disease. There is no approved medical therapy. ENB-0040 is a bone-targeted, recombinant human TNSALP that prevents the manifestations of hypophosphatasia in Tnsalp knockout mice.
Keyword(s):
enzyme-replacement therapy, hypophophatasia
Product/Publication Type(s):
Peer-reviewed publications in scholarly journals Published/In Press
Target Audience:
Professionals, Students
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A